Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Clinical Trial ID NCT00085566

Rank	Title	Journal	Year	PubWeight™‹?›
1	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.	Mol Cancer	2010	1.87
2	Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.	Curr Cancer Drug Targets	2009	1.66
3	Experimental approaches for the treatment of malignant gliomas.	Pharmacol Ther	2010	1.23
4	Novel targeted therapeutics for metastatic castration-resistant prostate cancer.	Cancer Lett	2009	1.04
5	PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.	Oncotarget	2016	1.02
6	A framework for understanding and targeting residual disease in oncogene-driven solid cancers.	Nat Med	2016	0.91
7	The mTOR signaling pathway as a treatment target for intracranial neoplasms.	Neuro Oncol	2014	0.84
8	Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.	Sci Rep	2015	0.82
9	Research in castration-resistant prostate cancer: what does the future hold?	Curr Oncol	2010	0.79
10	Targeted therapy in the treatment of malignant gliomas.	Onco Targets Ther	2009	0.78
11	Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.	Cancer	2015	0.76
12	Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors.	PLoS One	2015	0.75